Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 79,590 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 79,590 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $17.73, for a total value of $1,411,130.70. Following the completion of the sale, the insider directly owned 315,978 shares in the company, valued at approximately $5,602,289.94. This represents a 20.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Francis Lo also recently made the following trade(s):

• On Friday, January 2nd, Francis Lo sold 3,125 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.08, for a total value of $50,250.00.
• On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.50, for a total value of $76,895.00.
• On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.57, for a total transaction of $1,773,267.30.

Adaptive Biotechnologies Trading Down 0.2%

Shares of ADPT stock traded down $0.03 on Wednesday, hitting $18.04. 1,865,999 shares of the stock were exchanged, compared to its average volume of 1,982,211. The business has a 50-day moving average of $16.50 and a 200 day moving average of $14.44. The firm has a market capitalization of $2.75 billion, a P/E ratio of -33.41 and a beta of 2.18. Adaptive Biotechnologies Corporation has a fifty-two week low of $6.26 and a fifty-two week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. The firm had revenue of $93.97 million for the quarter, compared to the consensus estimate of $58.76 million. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The business’s revenue was up 102.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.22) earnings per share. As a group, research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Hedge funds have recently added to or reduced their stakes in the stock. Sound Income Strategies LLC acquired a new stake in Adaptive Biotechnologies in the third quarter valued at $30,000. Smartleaf Asset Management LLC increased its stake in Adaptive Biotechnologies by 593.5% during the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock valued at $59,000 after purchasing an additional 3,371 shares during the last quarter. Caxton Associates LLP bought a new position in shares of Adaptive Biotechnologies in the first quarter worth $93,000. Quadrant Capital Group LLC bought a new position in shares of Adaptive Biotechnologies in the third quarter valued at $133,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Adaptive Biotechnologies during the 2nd quarter worth about $134,000. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on ADPT shares. BTIG Research raised their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Morgan Stanley assumed coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price for the company. Guggenheim assumed coverage on Adaptive Biotechnologies in a report on Tuesday, September 30th. They set a “buy” rating and a $20.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on shares of Adaptive Biotechnologies from $17.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Finally, Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $17.11.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.